Akero TherapeuticsAKRO
About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Employees: 63
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
80% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 9 (+4) [Q4]
25% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 51
12% more funds holding
Funds holding: 168 [Q3] → 188 (+20) [Q4]
5% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $16.3M
0.3% more ownership
Funds ownership: 105.96% [Q3] → 106.26% (+0.3%) [Q4]
2% less capital invested
Capital invested by funds: $2.11B [Q3] → $2.06B (-$47M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
HC Wainwright & Co. Ed Arce 36% 1-year accuracy 40 / 111 met price target | 79%upside $75 | Buy Maintained | 3 Mar 2025 |
UBS Eliana Merle 44% 1-year accuracy 4 / 9 met price target | 160%upside $109 | Buy Maintained | 31 Jan 2025 |
B of A Securities Alexandria Hammond 100% 1-year accuracy 1 / 1 met price target | 50%upside $63 | Buy Upgraded | 30 Jan 2025 |
Morgan Stanley Michael Ulz 22% 1-year accuracy 4 / 18 met price target | 129%upside $96 | Overweight Maintained | 28 Jan 2025 |
Citigroup Jonathan Woo 50% 1-year accuracy 1 / 2 met price target | 91%upside $80 | Buy Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 14 articles about AKRO published over the past 30 days









